Contrast-enhanced ultrasound (CEUS) imaging for active surveillance of small renal masses.

Abstract

To assess the safety and efficacy of contrast-enhanced ultrasound (CEUS) imaging for monitoring small (< 4cm) renal masses (SRM) in patients undergoing active surveillance (AS). We retrospectively selected all consecutive patients with SRMs who underwent AS for at least 6months at our Institution between January 2014 and December 2018. CEUS imaging was performed by two experienced genitourinary radiologists at established time points. The accuracy of CEUS for monitoring SRM size was compared with that of CT scan. For solid SRMs, four enhancement patterns (EP) were recorded. Radiological progression was defined as SRM growth rate ≥ 5mm/year. Overall, 158/1049 (15.1%) patients with SRMs underwent AS. At a median follow-up of 25months (IQR 13-39), no patient died due to renal cell carcinoma (RCC). No patients experienced CEUS-related adverse events. There was a large variability in the pattern of growth of SRMs (overall median growth rate: 0.40mm/year), with 9.5% of SRMs showing radiological progression. The median SRM size was comparable between CEUS and CT scan examinations at all time points. The vast majority (92.7%) of SRMs did not show a change in their EP over time; and there was no association between the SRM's EP and radiological progression or SRM size. Overall, 43 (27.2%) patients underwent delayed intervention (DI); median SRM size, and median growth rate were significantly higher in these patients as compared to those continuing AS. In experienced hands, CEUS is a safe and effective strategy for active monitoring of SRMs in well-selected patients undergoing AS.